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SHORT REPORT
Elimination of congenital rubella: a seroprevalence study of pregnant women and
women of childbearing age in Italy
Serena Marchi a, Simonetta Viviani a, Emanuele Montomoli a,b, and Claudia Maria Trombetta a
aDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy; bVisMederi srl, Siena, Italy
ABSTRACT
Prevention of congenital rubella is achieved by vaccination of susceptible women of childbearing age. In
Italy, the National Plan for Measles and Congenital Rubella Elimination 2010–2015 implemented catch-
up vaccination activities targeting susceptible adolescents and young adults, including women of
childbearing age. The aim of this study was to assess the immunity against rubella in women of
childbearing age in Tuscany (Central Italy) and Apulia (Southern Italy) and pregnant women in Apulia
after the implementation of the National Plan for Measles and Congenital Rubella Elimination. Overall,
anti-rubella IgG prevalence in women of childbearing age samples was 88.6% in Tuscany and 84.3% in
Apulia. The lowest prevalence was observed in samples of 26–35 years old women of childbearing age
in Apulia with 77.8%. Only 62.7% of samples from 26–35 years old pregnant women had IgG against
rubella, and one sample out of 95 was positive to IgM. The findings of this study highlight the need for
increasing awareness on the risk of contracting rubella infection during pregnancy and implement
vaccination strategies to create opportunities for administration of rubella containing vaccines in young
girls and women of childbearing age.
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Introduction
Rubella is a highly contagious viral disease usually affecting
children and young adults; if contracted during pregnancy may
lead to miscarriage, premature delivery or congenital defects
known as Congenital Rubella Syndrome (CRS). The highest
risk of CRS is associated with high rates of susceptibility to
rubella among women of childbearing age (WOCBA).1
In Italy, live attenuated vaccines against rubella were avail-
able since 1972 and were recommended for adolescent girls
only. Starting from 1990, immunization with the combined
measles-mumps-rubella (MMR) vaccine was recommended
for children within the second year of life, but was offered
free of charge only by some regions, mainly located in
Northern and Central Italy. In 1999 MMR vaccine was
included in the national immunization schedule and one
dose was recommended in children between 12 and 15 months
of age.2 In 2003, Italy approved the first National Plan of
Measles and Congenital Rubella Elimination (NPMCRE
2003–2007), targeting to reducing CRS below 1/100,000 live
births per year by 2007. The operating goals introduced a two-
doses schedule with MMR vaccine in all regions with
a booster dose at 5–6 years of age and catch-up vaccinations
of older children, adolescents and WOCBA.3,4 As elimination
goal for measles and congenital rubella was not achieved,
NPMCRE was renewed for 2010–2015 (NPMCRE
2010–2015) and in the National Immunization Prevention
Plan for 2017–2019 (PNPV 2017–2019).5-7
In Italy, a national passive surveillance system for conge-
nital rubella and rubella in pregnancy is active since 2005.8
According to the Italian National Institute of Health (ISS)
surveillance data, from January 2005 to February 2018
a total 173 cases of rubella in pregnancy and 88 cases of
congenital rubella were reported.9 Although the incidence of
congenital rubella was below the World Health Organization
target of 1/100,000 live births, except for two peaks in 2008
and 2012 (5 and 4/100,000, respectively),10 the underreporting
to the national surveillance system should be taken into
account as it is estimated to be >50%.11
The present study was performed to assess the profile of
rubella susceptibility in WOCBA and in pregnant women in
two large Italian regions after the implementation of
NPMCRE for 2010–2015.
Methods
The study was performed on serum samples anonymously
stored at the serum bank of the Laboratory of Molecular
Epidemiology, Department of Molecular and Developmental
Medicine of the University of Siena. Samples were collected
for various medical checks in compliance with Italian law on
Ethics in the province of Siena (Tuscany region, Central Italy)
and Bari (Apulia region, Southern Italy) between 2014 and
2016. For each sample information available were age, gender,
date and place of sampling. For serum samples collected in
Bari, state of pregnancy was also available.
Out of a total of 2500 available serum samples of women
between 15 and 45 years of age, 899 were randomly selected by
using a computer generated randomization list, stratified by age
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groups of 15–25, 26–35 and 36–45 years and tested for the pre-
sence of specific anti-rubella IgG. In addition, 95 serum samples
collected in Bari of pregnant women were randomly selected and
stratified in two age groups of 26–35 and 36–45 years and tested
for the presence of anti-rubella IgG and IgM.
Specific anti-rubella antibodies were detected by commercial
ELISA kits ENZYWELL Rubella IgG and ENZYWELL Rubella
IgM, kindly provided by DIESSE (Siena, Italy). Samples were
tested using a qualitative method, as indicated by manufactured
instructions. Samples were considered positive for IgG when the
ratio between the optical density of the sample and that of the
cutoff was >1.3, while negative if the ratio was <0.7. Samples
were considered positive for IgM with a ratio >1.2 and negative
with a ratio <0.8. Samples with borderline result (between 0.7
and 1.3 for IgG and between 0.8 and 1.2 for IgM) were retested.
For IgG, the cutoff used corresponded to 10 IU/ml, considered
the correlate of protection for rubella.1
Seroprevalence rates were calculated along with the corre-
sponding 95% confidence intervals (CI). Fisher’s exact test
and Chi-square test for trend were used for statistical analysis
using GraphPad Prism 6 software; statistical significance was
set at p < .05, two tailed.
Results
Of the 899 samples tested in total, 57 were borderline and
were retest. At retest, still 34 had borderline results and there-
fore were excluded from the analysis. The mean age of
WOCBA was 34 (±7.5) years for Siena samples and 31.7
(±8.1) years for Bari samples. The mean age of pregnant
women samples was 33.7 (±4) years. Figure 1 shows the
distribution of samples suitable for statistical analysis by age
group and place of sampling.
In WOCBA samples collected in Siena, the positivity rate
was 88.6% (85.1–91.4; 343/387) and a trend toward increase
with age is present (p = .005). 80.0% (68.6–88.1; 52/65) of
samples belonging to 15–25 years old age group showed immu-
nity against rubella, followed by 87.3% (80.5–92.0; 117/134)
and 92.5% (87.8–95.6; 174/188) in 26–35 and 36–45 years old
age groups, respectively. In Bari, the overall seroprevalence was
84.3% (80.3–87.6; 323/383) and a significant lower seropreva-
lence was observed in WOCBA 26–35 years old age group
(77.8%, 70.9–83.5; 130/167) in comparison to the other two
age groups (15–25 years old: 90.1%, 82.1–94.9; 82/91 and
36–45 years old: 88.8%, 82.0–93.3; 111/125) (p = .022 vs
both). WOCBA 26–35 years old age group samples from Bari
were found to be significantly lower also compared to samples
of the same age group from Siena (p = .035).
A total of 67.4% (57.4–76.0; 64/95) of pregnant women
samples from Bari had antibody against rubella. 62.7% (50.-
7–73.3; 42/67) of samples of the 26–35 years old age group
and 78.6% (60.1–90.1; 22/28) of the 36–45 years old age group
were found to be positive. Comparing WOCBA samples from
Bari with the pregnant women samples of the same age,
a significant difference was found (p < .001), especially
between the 26–35 years old age groups of the two population
(p = .022). One pregnant woman belonging to the 26–35 age
group (1.1%, 0–6.3; 1/95) was found to be positive for anti-
rubella IgM, as well as positive for IgG.
Discussion
Prevention of congenital rubella is achieved by maintaining high
levels of vaccine coverage (> 95%) in the general population and
identification and vaccination of susceptible WOCBA. This ser-
oprevalence study was conducted to evaluate whether the objec-
tive of the NPMCRE 2010–2015 of increasing immunity to rubella
in WOCBA in two different Italian provinces, Siena (Tuscany)
and Bari (Apulia), was achieved. Moreover, immunity to rubella
was also assessed in a sample of pregnant women from Bari.
Overall, immunity to rubella in WOCBA samples was similar in
Siena and Bari, with some significant differences by age groups. In
Siena, 20% of WOCBA subjects between 15 and 25 years old had
no immunity to rubella. These data are consistent with those
published by the Ministry of Health in 2016, where in Tuscany
region the 18-year-old subjects (born in 1998) had a vaccine
coverage of 85.5% and 79% for the first and second dose, respec-
tively, of rubella containing vaccine.12 In Bari, immunity to rubella
in the WOCBA 15–25 years old group was 90%. This value is
higher than reported in a seroepidemiological study conducted in
2011–2012.13 The higher proportion of samples with immunity to
rubella is most likely due to vaccination campaign for MMR
implemented within the framework of NPMCRE 2010–2015.
The impact of that vaccination campaign in Apulia region was
such that coverage for MMR increased from 87.7% for the first
dose and 75.9% for the second dose in 18-years old subjects (born
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Figure 1. Anti-rubella IgG prevalence in WOCBA from Siena and Bari, and in pregnant women from Bari between 2014 and 2016 by age groups.
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in 1998) to 92.5% and 82.7% respectively in 16-years-old subjects
(born in 2000).12,14 However, only 77% of WOCBA samples of
26–35 years old group had immunity to rubella, which is of
concern if we consider that in Italy the mean age at the delivery
in 2016 was 31.8 years and for most women is the only pregnancy
as the total fertility rate per woman is 1.34.15 WOCBA lacking
immunity to rubella were born between 1979 and 1990, but catch-
up vaccination campaign in school planned by NPMCRE since
2003 targeted only women born between 1991 and 1997
(NPMCRE 2003–2007). Therefore, those WOCBA lacking pro-
tective immunity have probably missed vaccination offered by
catch-up programmes.13 Meanwhile, the concomitant decrease
in the circulation of wild-type virus has reduced the possibility
of natural infection-induced immunity. On the other hand, older
women born in the 70s, during a high natural virus circulation
period, show significantly higher antibody prevalence, possibly
because of the higher antibody levels induced by natural infection.
In fact, a survey conducted in 1985 showed that the vaccine
coverage for rubella in 10 years old girls, the target population
for rubella immunization at the time, was 11.3% and 6.1% in
Central and Southern Italy, respectively.16
In Bari, the immunity gap for pregnant women samples of
the 26–35 years old group, and to less extent to the 36–45 one,
is of particular concern as a substantial proportion of the
neonates are at high risk of CRS. In addition, the detection
of IgM in one sample of pregnant women of 26–35 years old
group suggests that rubella virus circulates in this population
to an extent that may be wider than what we detected in the
limited sample size of this study. The gap in immunity to
rubella observed between WOCBA and pregnant women in
samples from Bari may also be explained by the fact that
a proportion of pregnant women population may be repre-
sented by women of recent immigration to Italy. In fact,
surveillance data of CRS in Italy reported that 17% of preg-
nant women who had contracted rubella infection during
pregnancy were not Italian and their mean age was 27 years.9
This study has some limitations. Samples may not be
representative of the WOCBA or pregnant women population
as they were taken for reasons different from the objectives of
the study. Limited information was available such as the
vaccination status or the trimester of pregnancy.
The Italian Behavioral Risk Factor Surveillance System
(PASSI) showed that in the 2013–2016 period, 39.1% of
WOCBA had an unknown immune status against rubella or
was susceptible to rubella, 17 suggesting a low level of awareness
about the risk of contracting the infection during pregnancy. In
Italy, rubella test is offered free of charge as pre-conception
screening and rubella vaccination is offered to susceptible
women in any opportunities of encounter (i.e., the anti-
tetanus-diphtheria-pertussis booster dose, the anti-human
papilloma virus vaccine administration, the first pap-test
screening, after delivery or after abortion) (NPMCRE
2010–2015). However, as already observed for other vaccine-
preventable diseases,18,19 the vaccination strategy based on the
passive offer seems to be not enough for the achievement of the
NPMCRE objective to reduce the percentage of susceptible
females below 5%.4,13
In conclusion, in Italy in 2017, the vaccine coverage for
rubella in 16-years-old adolescents (born in 2001) is about
85% for the first dose and 83% for the second dose of MMR
vaccine, 20 meaning that a considerable proportion of women
entering to childbearing age are susceptible to rubella. It is
therefore necessary to develop additional vaccination strate-
gies that will target both Italian and recently immigrant
women in order to reduce the pocket of susceptibility to
rubella in young girls and WOCBA.
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